



## Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

November 17, 2025

CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:

### **Jefferies Global Healthcare Conference in London**

Thursday, Nov. 20, 2025 at 8:30 A.M. GMT (3:30 A.M. ET)

The presentation will be webcast live and may be accessed [here](#).

### **8th Annual Evercore Healthcare Conference**

Tuesday, Dec. 2, 2025 at 4:15 P.M. ET

The presentation will be webcast live and may be accessed [here](#).

### **Piper Sandler 37<sup>th</sup> Annual Healthcare Conference**

Wednesday, Dec. 3, 2025 at 1:30 P.M. ET

The presentation will be webcast live and may be accessed [here](#).

The fireside chats will be webcast live and can be accessed by visiting Madrigal's Investor Relations Events [page](#).

### **About Madrigal**

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal's medication, Rezdifra (resmetirom), is a once-daily, oral, liver-directed THR- $\beta$  agonist designed to target key underlying causes of MASH. Rezdifra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdifra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit [www.madrigalpharma.com](http://www.madrigalpharma.com).

### **Investor Contact**

Tina Ventura, [IR@madrigalpharma.com](mailto:IR@madrigalpharma.com)

### **Media Contact**

Christopher Frates, [media@madrigalpharma.com](mailto:media@madrigalpharma.com)



Source: Madrigal Pharmaceuticals, Inc.